Müller-Oerlinghausen B - Search Results

1

Predictors of therapeutic effects in amitriptyline treatment--1. Plasma drug levels.

Franke L, Schewe HJ, Uebelhack R, Müller-Oerlinghausen B. Franke L, et al. Pharmacopsychiatry. 2003 Jul;36(4):134-42. doi: 10.1055/s-2003-41198. Pharmacopsychiatry. 2003. PMID: 12905099 Clinical Trial.

2

Blood dyscrasias induced by psychotropic drugs.

Stübner S, Grohmann R, Engel R, Bandelow B, Ludwig WD, Wagner G, Müller-Oerlinghausen B, Möller HJ, Hippius H, Rüther E. Stübner S, et al. Pharmacopsychiatry. 2004 Mar;37 Suppl 1:S70-8. doi: 10.1055/s-2004-815513. Pharmacopsychiatry. 2004. PMID: 15052517

3

The AGNP-TDM expert group consensus guidelines: therapeutic drug monitoring in psychiatry.

Baumann P, Hiemke C, Ulrich S, Eckermann G, Gaertner I, Gerlach M, Kuss HJ, Laux G, Müller-Oerlinghausen B, Rao ML, Riederer P, Zernig G; Arbeitsge-meinschaft fur neuropsychopharmakologie und pharmakopsychiatrie. Baumann P, et al. Pharmacopsychiatry. 2004 Nov;37(6):243-65. doi: 10.1055/s-2004-832687. Pharmacopsychiatry. 2004. PMID: 15551191 Review.

4

Effect of prophylactic treatment on suicide risk in patients with major affective disorders. Data from a randomized prospective trial.

Thies-Flechtner K, Müller-Oerlinghausen B, Seibert W, Walther A, Greil W. Thies-Flechtner K, et al. Pharmacopsychiatry. 1996 May;29(3):103-7. doi: 10.1055/s-2007-979553. Pharmacopsychiatry. 1996. PMID: 8738314 Clinical Trial.

5

The outpatient clinic for patients under chronic lithium or neuroleptic treatment as a phase-IV research tool.

Pietzcker A, Müller-Oerlinghausen B. Pietzcker A, et al. Pharmacopsychiatry. 1984 Sep;17(5):162-7. doi: 10.1055/s-2007-1017430. Pharmacopsychiatry. 1984. PMID: 6149570

6

Lithium long-term treatment--does it act via serotonin?

Müller-Oerlinghausen B. Müller-Oerlinghausen B. Pharmacopsychiatry. 1985 Mar;18(2):214-7. doi: 10.1055/s-2007-1017367. Pharmacopsychiatry. 1985. PMID: 3927331

7

The influence of phototherapy on serotonin and melatonin in non-seasonal depression.

Rao ML, Müller-Oerlinghausen B, Mackert A, Stieglitz RD, Strebel B, Volz HP. Rao ML, et al. Pharmacopsychiatry. 1990 May;23(3):155-8. doi: 10.1055/s-2007-1014499. Pharmacopsychiatry. 1990. PMID: 2374773 Clinical Trial.

8

Value and actuality of the prescription information for therapeutic drug monitoring of psychopharmaceuticals: a comparison with the medico-scientific evidence.

Ulrich S, Hiemke C, Laux G, Müller-Oerlinghausen B, Havemann-Reinecke U, Riederer P, Zernig G, Baumann P; TDM group of the Arbeitsgemeinschaft Neuropsychopharmakologie und Pharmakopsychiatrie (AGNP). Ulrich S, et al. Pharmacopsychiatry. 2007 May;40(3):121-7. doi: 10.1055/s-2007-977712. Pharmacopsychiatry. 2007. PMID: 17541888

9

Genetic determinants of drug-induced agranulocytosis: potential risk of olanzapine?

Dettling M, Cascorbi I, Hellweg R, Deicke U, Weise L, Müller-Oerlinghausen B. Dettling M, et al. Pharmacopsychiatry. 1999 May;32(3):110-2. doi: 10.1055/s-2007-979204. Pharmacopsychiatry. 1999. PMID: 10463379

10

Clozapine treatment of HIV-associated psychosis--too much bone marrow toxicity?

Dettling M, Müller-Oerlinghausen B, Britsch P. Dettling M, et al. Pharmacopsychiatry. 1998 Jul;31(4):156-7. doi: 10.1055/s-2007-979320. Pharmacopsychiatry. 1998. PMID: 9754853 No abstract available.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

Search Page

Search Results